These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Author: Moore MJ, Iscoe N, Tannock IF.
    Journal: J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371.
    Abstract:
    The use of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) to treat transitional cell carcinoma is associated with high rates of granulocytopenia. To test whether the addition of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) would decrease the hematological toxicity of M-VAC 21 patients were treated with standard dose M-VAC (30 mg./m.2 methotrexate on days 1, 15 and 22, 3 mg./m.2 vinblastine on days 2, 15 and 22, 30 mg./m.2 doxorubicin on day 2 and 70 mg./m.2 cisplatin on day 2) plus 5 micrograms./kg. rhGM-CSF subcutaneously on days 4 to 13. On cycles 1 and 2 of therapy grade III or greater granulocytopenia (less than 1.0 x 10(9)/l.) was noted in 39% and 43% of the patients, respectively, and the majority were able to receive the day 15 and day 22 treatments as scheduled. This was an apparent improvement over our historical experience with M-VAC alone (p = 0.03). By cycle 3 of treatment this beneficial effect of rhGM-CSF was no longer apparent, with 80% of the patients experiencing grade III or greater granulocytopenia and thrombocytopenia also becoming apparent. Seven patients had to discontinue rhGM-CSF because of side effects. It is unlikely that clinically significant escalation of chemotherapy dosages can be achieved with M-VAC and rhGM-CSF.
    [Abstract] [Full Text] [Related] [New Search]